Brokerages Set Artelo Biosciences, Inc. (NASDAQ:ARTL) PT at $24.00

Shares of Artelo Biosciences, Inc. (NASDAQ:ARTL) have been assigned an average recommendation of “Hold” from the six brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $24.00.

Several analysts recently weighed in on ARTL shares. Maxim Group restated a “hold” rating on shares of Artelo Biosciences in a report on Wednesday. D. Boral Capital reiterated a “hold” rating on shares of Artelo Biosciences in a research report on Monday, September 8th. Wall Street Zen downgraded shares of Artelo Biosciences to a “strong sell” rating in a research note on Saturday, August 9th. D Boral Capital cut shares of Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artelo Biosciences in a report on Tuesday, November 11th.

Artelo Biosciences Trading Down 2.3%

Shares of NASDAQ ARTL opened at $1.67 on Monday. Artelo Biosciences has a 12-month low of $1.55 and a 12-month high of $28.60. The firm’s 50-day moving average price is $3.74 and its 200-day moving average price is $7.30. The stock has a market capitalization of $3.37 million, a price-to-earnings ratio of -0.08 and a beta of 1.23.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($3.97) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($3.15). On average, equities analysts predict that Artelo Biosciences will post -2.62 EPS for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.